DUBLIN – Ablynx NV joined the great European biopharma migration to Nasdaq, grossing just over $200 million in an upsized IPO of 11.43 million shares, which it priced at $17.50 per American Depository Share (ADS). The offering brings its total number of shares outstanding to over 72.8 million and implies a market cap just shy of $1.3 billion.